Trial Profile
A multicenter, observational cohort study investigating safety and efficacy of telaprevir or simeprevir-based regimens in Italian patients with chronic hepatitis C infection
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2018
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms Stily
- Sponsors Janssen-Cilag
- 01 Jul 2018 Results (n=349) published in the Medicine.
- 10 May 2016 New trial record
- 17 Apr 2016 Interim results (n= 338) assessing effectiveness presented at The International Liver Congress™ 2016